A

Amgen

Makes biotech medicines for serious illnesses

AI Security Engineer

Full-TimeUpdated on 10/24/2026
€52.3k - €70.8k
Senior
Bachelor's, Master's
Lisbon, Portugal
HybridHybrid work split between the Lisbon office and remote work; domestic and international travel up to 10%.
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • Bachelor’s or Master’s degree in Computer Science, Cybersecurity, Engineering, Information Technology, or a related technical field, or equivalent practical experience.
  • 5+ years of hands-on experience in cybersecurity, security engineering, application security, cloud security, or a related technical discipline, including experience securing modern cloud-based applications and platforms.
  • Strong programming or scripting skills to build security tooling, automation, integrations, and proof-of-concept implementations.
  • Strong understanding of application security fundamentals, including authentication and authorization, API security, secrets management, cryptography, input/output validation, software supply chain security, and common application vulnerabilities.
  • Hands-on experience with cloud-native technologies, preferably AWS.
  • Practical knowledge of threat modeling and security testing, and the ability to translate identified risks into technical mitigations and security controls.
  • Understanding of AI/ML systems and the AI development lifecycle, including model training, inference, APIs, data pipelines, and MLOps/LLMOps.
  • Familiarity with security risks associated with large language models and generative AI, including prompt injection, sensitive information disclosure, insecure output handling, excessive agency, model and data supply chain risks, and insecure tool integrations.
  • Familiarity with AI agents, RAG architectures, vector databases, embeddings, model APIs, and AI application frameworks.
  • Experience designing, developing, and automating agentic AI workflows and pipelines, including multi-step and tool-enabled agent architectures, using platforms and frameworks such as n8n, Databricks Agent Bricks, Amazon Bedrock Agents, or similar technologies.
  • Ability to manage competing demands, adapt quickly to changing priorities, and maintain high-quality outcomes under time pressure in a fast-paced and rapidly evolving AI environment.
  • Familiarity with AI-focused security frameworks and guidance such as OWASP guidance for LLM and GenAI applications, MITRE ATLAS, and the NIST AI Risk Management Framework.
  • Fluency in English.
Responsibilities
  • Design and implement AI security controls for AI/ML applications, platforms, models, APIs, agents, and supporting infrastructure.
  • Deploy security tooling and automation, primarily using AWS cloud infrastructure and APIs, to integrate AI security testing and controls into engineering workflows.
  • Integrate security into MLOps, LLMOps, DevSecOps, and CI/CD pipelines to enable automated security validation throughout the AI development lifecycle.
  • Threat model AI systems and applications, translating identified risks into practical engineering requirements, mitigations, tests, and security controls.
  • Secure generative AI and agentic AI systems, including model endpoints, retrieval-augmented generation (RAG), vector databases, tools, agent workflows, identity boundaries, and external integrations.
  • Evaluate and integrate AI security technologies, including capabilities for AI runtime protection, model and application testing, data protection, observability, and AI security posture management.
  • Implement security controls for cloud-based AI platforms and services across enterprise cloud environments.
  • Secure containerized AI workloads running on technologies such as Docker and Kubernetes, including workload identity, secrets management, network controls, runtime security, and policy enforcement.
  • Implement infrastructure and security controls as code using technologies such as Terraform, cloud-native infrastructure-as-code tooling, or similar technologies.
  • Partner with AI and platform engineering teams to investigate threats, develop mitigations, and drive identified security issues through remediation.
  • Support security reviews of AI systems and provide actionable engineering recommendations and practical solutions.
  • Deploy monitoring and detection capabilities for security-relevant AI activity, misuse patterns, anomalous behavior, and emerging attack techniques.
  • Build AI security standards and technical guidance, translating security, regulatory, and risk requirements into implementable technical controls.
  • Share technical knowledge across cybersecurity and engineering teams and contribute to the continued development of Amgen’s AI security capabilities.
  • Travel domestically and internationally up to 10%.
Desired Qualifications
  • Experience with AI/ML development frameworks such as PyTorch, TensorFlow, Hugging Face, LangChain, or similar technologies.
  • Experience with MLOps and AI platforms such as MLflow, SageMaker, or equivalent platforms.
  • Understanding of data protection techniques, including encryption, data classification, DLP, anonymization, tokenization, and privacy-enhancing technologies.
  • Familiarity with regulated environments and requirements such as GxP, GDPR, the EU AI Act, and HIPAA.
  • Ability to communicate complex AI security issues clearly and translate them into practical engineering actions.
  • Relevant security certifications such as CISSP, CCSP, cloud security certifications, or AI security certifications.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.